NCT07357649Not yet recruitingPhase 4
Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis
Prospective Evaluation of Baricitinib's Effects on Procoagulant State and Atherogenic Index in Rheumatoid Arthritis Patients
Source: ClinicalTrials.gov · Last updated 22 Jan 2026
Brief summary (registry, in English)
This prospective interventional study aims to evaluate the effects of baricitinib on disease activity, lipid profile, atherogenic index, and procoagulant biomarkers including monocyte-derived human tissue factor and D-dimer in patients with rheumatoid arthritis, compared with conventional therapy.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 12 Jan 2026
- Start date
- Jan 2026
- Primary completion date
- Apr 2026
- Lead sponsor
- Tanta University
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07357649
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- From Jan 2026 to the primary completion date, Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Dyslipidemia or use of lipid-lowering therapy within the last 6 months.
- Alcohol or drug abuse.
- Use of anticoagulant or antithrombotic drugs within the last 3 months.
Other illness
- Presence of other autoimmune diseases.
- Diabetes mellitus.
- Chronic kidney disease.
- Chronic liver disease.
- Chronic respiratory disease.
- History of malignancy.
- Acute or chronic infection.
- History of arterial or venous thrombosis.
Other
- Pregnancy or breastfeeding.
- Current prednisone dose \> 7.5 mg/day.
Who the study is looking for
- Adults aged ≥ 18 years.
- Diagnosis of rheumatoid arthritis according to the ACR/EULAR 2010 criteria.
- Patients with active rheumatoid arthritis despite conventional treatment.
- Ability to provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta University Hospitals Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.